Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
This study is to determine whether canakinumab is able to induce and maintain a clinically
meaningful reduction of disease activity in participants with Hereditary Periodic Fevers
(HPF) compared to placebo.